Skip to main content
Loading
Sign In
Families and Youth
Toggle
Advocacy
Ethics
Facts for Families
Family Resources
Getting Help
Resource Centers
Youth Resources
Support AACAP
Medical Students & Residents
Toggle
Child Psychiatry Residents (Fellows)
Early Career Psychiatrists
Medical Student Resources
Member Resources
Toggle
Advocacy
Assembly of Regional Organizations
Award Opportunities
Become a Member
Clinical Practice Center
CPT and Reimbursement
Early Career Psychiatrists
Education Center
Ethics
International
Job Source
Life Members
Maintenance of Certification
Research
Resources for Primary Care
Toggle
Advocacy and Policy
Become a Member
Clinical Practice Center
Ethics
Information for Patients and Their Families
Integrated Care For Kids
Integrating Mental Health Care into the Medical Home
Practice Parameters and Resource Centers
CME & Meetings
Toggle
2020 Annual Meeting
2021 Virtual Pediatric Psychopharmacology Update Institute
Learning on Demand
Maintenance of Certification and Lifelong Learning Modules
Online CME
Pathways
My Profile
Store
Cart
Donate
Join AACAP
Toggle search
Toggle navigation
Quick Links
Family Resources
Resource Centers
Youth Resources
Child and Adolescent Psychiatrist Finder
Facts For Families
ADHD Medication
AACAP Testimony at the March 22 FDA Pediatric Advisory Committee Meeting
3/22/06
AACAP Statement on FDA Advisory On Methylphenidate
3/22/06
FDA Statement on Adderall
Canadian Advisory
AACAP President's Email to Members
Cardiovascular Monitoring of Children and Adolescents Receiving Psychotropic Drugs
American Heart Association (see Other Resources below), as reprinted in JAACAP, 1999
{1}
##LOC[OK]##
{1}
##LOC[OK]##
##LOC[Cancel]##
{1}
##LOC[OK]##
##LOC[Cancel]##
